Fortem Financial Group’s Scinai Immunotherapeutics SCNI Stock Holding History

Fortem Financial Group’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1	Closed	–	–	389
2020 Q4	$0	Buy	+1	New	+$1.21K	﹤0.01%	466

Other funds holding SCNI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TPWA

TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fortem Financial Group's SCNI Position: Q1 2021 in Review

Fortem Financial Group sold out of Scinai Immunotherapeutics (SCNI) in Q1 2021, closing a stake of 1 share.

Fortem Financial Group first reported a position in SCNI in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 18 funds tracked by Wall St. Rank hold SCNI as of Q1 2021.

Fortem Financial Group reported no remaining Scinai Immunotherapeutics position as of Q1 2021 after selling out during the quarter.
Fortem Financial Group sold 1 Scinai Immunotherapeutics share in Q1 2021.
Fortem Financial Group first reported a position in Scinai Immunotherapeutics in Q4 2020 and held it in 1 quarter.
Fortem Financial Group's Scinai Immunotherapeutics position peaked at $0 in Q4 2020.
18 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2021.

Based on Fortem Financial Group's 13F filing for Q1 2021, filed 20 Apr 2021.